You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Microsatellite Instability-High (MSI-H)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

Not yet recruiting
  • Adenocarcinoma - GEJ
  • Gastric Adenocarcinoma
  • (no location specified)
Sep 26, 2023

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

Completed
  • Recurrent/Metastatic Gastric Cancer
  • Nivolumab, Paclitaxel
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Sep 9, 2022

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

Recruiting
  • Colorectal Cancer
  • +3 more
  • Neoadjuvant therapy with PD-L1 inhibitor
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022

Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

Recruiting
  • Colorectal Carcinoma
  • Guangzhou, China
    Sun Yat-sen University
Dec 29, 2022

MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

Terminated
  • MSI-H/dMMR Solid Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 17, 2022

Solid Tumor Trial in Beijing (KN035)

Recruiting
  • Solid Tumor
  • KN035
  • Beijing, Beijing, China
    Peking University Cancer Hospital, Peking University
Apr 5, 2022

Solid Tumors, Identified by NGS, PCR or IHC Trial in United States (Pembrolizumab)

Recruiting
  • Solid Tumors
  • Identified by NGS, PCR or IHC
  • Basking Ridge, New Jersey
  • +6 more
Oct 7, 2022

DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

Not yet recruiting
  • Endometrial Cancer
  • (no location specified)
Feb 14, 2023

Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • HX008
  • Investigator's Choice Chemotherapy
  • Hefei, Anhui, China
  • +9 more
Dec 8, 2022

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Colorectal Cancer Trial in China (Tislelizumab)

Recruiting
  • Colorectal Cancer
  • Bengbu, Anhui, China
  • +7 more
Sep 13, 2022

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) Trial (INCB 99280 with Ipilimumab)

Not yet recruiting
  • Melanoma
  • +5 more
  • INCB 99280 with Ipilimumab
  • (no location specified)
Jun 9, 2023

Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

Recruiting
  • Colorectal Cancer
  • Microsatellite Instability High
  • PD-1 inhibitor plus VEGF inhibitors
  • Guangzhou, Guangdong, China
    651 Dongfeng Road East
May 27, 2022

Melanoma Stage IV, Unresectable Melanoma, NSCLC Stage IV Trial in Ramat Gan (Fecal Microbial Transplantation by capsules)

Recruiting
  • Melanoma Stage IV
  • +2 more
  • Fecal Microbial Transplantation by capsules
  • Ramat Gan, Israel
    Sheba Medical Center
Aug 9, 2021

Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma Trial in Worldwide (LY3300054,

Active, not recruiting
  • Solid Tumor
  • +4 more
  • Nashville, Tennessee
  • +14 more
Jul 21, 2022

The mCRC pMMR/MSS or dMMR/MSI-H Status Received Palliative

Completed
  • Colorectal Cancer Metastatic
  • +2 more
    • Guangzhou, Guangdong, China
      Sun yat-sen university cancer center
    Jul 23, 2020

    Colorectal Tumors Trial in China (Pembrolizumab, Oxaliplatin, Leucovorin)

    Recruiting
    • Colorectal Neoplasms
    • Pembrolizumab
    • +6 more
    • Beijing, Beijing, China
    • +21 more
    Jan 25, 2023

    Endometrial Cancer Trial in United States (Intensity modulated radiation therapy (IMRT), Dostarlimab)

    Recruiting
    • Endometrial Cancer
    • Basking Ridge, New Jersey
    • +6 more
    Jul 5, 2022

    Colorectal Cancer Trial in Worldwide (Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab)

    Recruiting
    • Colorectal Cancer
    • Pembrolizumab
    • +4 more
    • Orange City, Florida
    • +54 more
    Aug 17, 2022